# Thymulin FAQ: Common Questions on the Research Record

> Thymulin FAQ: zinc dependency, age-related decline, thymalin vs thymulin, thymosin alpha-1 comparison, dosing, gene therapy, regulatory status, and NK cell research — answered from the peer-reviewed literature.

## Thymulin FAQ: Common Questions on the Research Record

Frequently asked questions on Thymulin, answered from the peer-reviewed research literature.

## What is thymulin?

Thymulin is a nonapeptide hormone (9 amino acids: pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) produced exclusively by thymic epithelial cells. Originally called serum thymic factor (FTS), it is biologically active only when bound to zinc in a 1:1 molar complex. The zinc-free form (apothymulin) has no immunological activity. It was characterized biochemically by Bach and Dardenne beginning in the early 1970s.[1, 2]

## What is thymulin peptide used for?

In the research record, Thymulin has been studied for T-cell differentiation, immune modulation (cytokine suppression via NF-kappaB inhibition), analgesic effects in rodent inflammatory and neuropathic pain models, neuroprotection in hippocampal astrocytes, and immunosenescence research. No approved human therapeutic indication exists.[2, 12, 14, 22]

## What are the benefits of thymulin peptide?

Rodent and in vitro studies document: immune restoration (reversed thymic involution and NK activity via zinc repletion[7]); cytokine modulation — upregulation of IL-10, suppression of TNF-alpha, IL-1beta, IL-6, IFN-gamma[12]; NK-cell enhancement in viral infection models[11]; analgesic activity in inflammatory pain models[14, 15]; and neuroprotection in hippocampal NF-kappaB inhibition models.[17] All evidence is pre-clinical or in vitro.

## What organs produce thymulin?

Thymulin is produced by two distinct epithelial cell populations within the thymus gland only. No other tissue has been identified as a production source. Production follows a circadian rhythm, peaking at approximately 1:00 a.m. in rodent studies.[22, 24]

## What does thymulin do?

Thymulin promotes T-lymphocyte differentiation and functional maturation by inducing expression of T-cell surface markers on immature thymocytes.[2, 4] It downregulates pro-inflammatory cytokines (TNF-alpha, IL-6, IFN-gamma) via NF-kappaB pathway inhibition[12, 13] and upregulates anti-inflammatory IL-10. It modulates the neuroendocrine-immune axis as a hypophysiotropic peptide (stimulating pituitary ACTH)[23] and acts on CNS astrocytes to reduce neuroinflammation.[17] All activity requires zinc binding.

## Does thymulin require zinc to work?

Yes. Zinc chelation abolishes biological activity; zinc re-addition restores it.[1] Only the Zn-thymulin complex binds the thymulin receptor on T-lymphocytes. The zinc-dependent epitope is structurally distinct from the zinc-free form, confirmed by monoclonal antibody assays and NMR in 1985.[3] Normal plasma zinc levels do not guarantee normal Zn-thymulin bioactivity — alpha-2-macroglobulin can sequester zinc competitively even when total zinc appears normal.[10]

## Why does thymulin decline with age?

Thymulin production tracks thymic involution, which begins at puberty and accelerates progressively. Concurrently, aging increases metallothionein expression in thymic tissue, which sequesters zinc and reduces its availability for Zn-thymulin formation.[8] Both mechanisms operate in parallel.

## At what age does thymulin start declining?

In a cross-sectional study of 93 healthy subjects from birth to age 80, serum thymulin titres peaked in children aged 5–10 years (mean 4.77), with lowest values recorded at age 36 (mean 0.66). Levels plateaued through age 80, remaining substantially below the childhood peak (Consolini et al., 2000).[6]

## What is the difference between thymalin and thymulin?

These are entirely different compounds. Thymulin is an endogenous human nonapeptide (9 amino acids, zinc-dependent, produced by the thymus). Thymalin is a polypeptide complex extracted from bovine thymus gland — a Khavinson bioregulator containing multiple peptides, not a single defined molecule. Different compound classes, different mechanisms, different research literatures. They are not interchangeable and should not be conflated.

| Property | Thymulin | Thymalin |
|---|---|---|
| Structure | 9-amino-acid nonapeptide (defined sequence) | Bovine thymus polypeptide extract (mixture) |
| Origin | Endogenous human hormone | Bovine gland extract |
| Zinc dependency | Yes — biologically inactive without zinc | Not applicable |
| Research base | Mechanism studies, immunosenescence, gene therapy | Khavinson bioregulator longevity studies |
| Regulatory status | No approved indication anywhere | Available in some countries (Russia) |

## Is thymulin the same as thymosin alpha-1?

No. Thymosin alpha-1 is a 28-amino-acid peptide derived from thymosin fraction 5 — structurally and mechanistically distinct from thymulin. They have separate research literatures, separate receptor targets, and separate proposed mechanisms.

| Property | Thymulin | Thymosin Alpha-1 |
|---|---|---|
| Length | 9 amino acids | 28 amino acids |
| Source | Endogenous thymic hormone | Synthetic fragment of thymosin fraction 5 |
| Zinc dependency | Yes — essential for activity | No |
| Primary mechanism | T-cell differentiation; NF-kappaB inhibition | TLR2/TLR9 agonist; dendritic cell activation |
| Clinical status | No approved indication | Approved in some countries (Italy, China) |

## Is thymulin FDA-approved as a therapeutic?

No. Thymulin has no FDA-approved therapeutic indication. It is not an approved drug or biological product in the United States, the European Union, or any major regulatory jurisdiction. No exogenous thymulin administration trials in humans have been published.

## Does zinc supplementation boost thymulin?

In zinc-deficient subjects, zinc repletion restores serum thymulin bioactivity by providing the zinc cofactor required for the Zn-thymulin complex.[5, 7] In zinc-sufficient subjects, additional zinc does not further boost thymulin above the saturation level. The relationship is a floor effect — sufficient zinc enables full bioactivity; deficiency disables it.

## What is thymulin gene therapy?

Thymulin gene therapy uses adenoviral vectors or DNA nanoparticles to deliver a synthetic thymulin gene (metFTS) into animal models to address age-related thymulin decline and its short plasma half-life (~10 min). Sustained thymulin expression for 112+ days was demonstrated in rodent models.[21] A 2020 Science Advances study used CK30PEG nanoparticles intratracheally to reverse experimental allergic asthma pathology within 20 days in mice.[26] All research is pre-clinical.

## References

[1] Dardenne M, et al. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci USA. 1982;79(17):5370-5373. https://pubmed.ncbi.nlm.nih.gov/6957870/
[2] Bach JF, Dardenne M. Thymulin, a zinc-dependent hormone. Med Oncol Tumor Pharmacother. 1989;6(1):25-29. https://pubmed.ncbi.nlm.nih.gov/2657247/
[3] Dardenne M, et al. A zinc-dependent epitope on the molecule of thymulin. Proc Natl Acad Sci USA. 1985;82(20):7035-7038. https://pubmed.ncbi.nlm.nih.gov/2413455/
[4] Incefy GS, et al. Induction of differentiation in human marrow T cell precursors by FTS. Clin Exp Immunol. 1980;40(3):396-406. https://pubmed.ncbi.nlm.nih.gov/6969145/
[5] Prasad AS, et al. Serum thymulin in human zinc deficiency. J Clin Invest. 1988;82(4):1202-1210. https://pmc.ncbi.nlm.nih.gov/articles/PMC442670/
[6] Consolini R, et al. Distribution of age-related thymulin titres in normal subjects. Clin Exp Immunol. 2000;121(3):444-447. https://pmc.ncbi.nlm.nih.gov/articles/PMC1905732/
[7] Mocchegiani E, et al. Reversibility of the thymic involution by zinc supplementation in old mice. Int J Immunopharmacol. 1995;17(9):703-718. https://pubmed.ncbi.nlm.nih.gov/8582782/
[8] Mocchegiani E, et al. Are zinc-bound metallothionein isoforms involved in impaired thymulin production? Immun Ageing. 2004;1:5. https://pmc.ncbi.nlm.nih.gov/articles/PMC544958/
[10] Mocchegiani E, et al. Role of zinc and alpha-2 macroglobulin on thymic endocrine activity in cervical carcinoma. Br J Cancer. 1999;79(3-4):358-365. https://pmc.ncbi.nlm.nih.gov/articles/PMC2362212/
[11] Oliver MA, Marsh JA. In vivo thymulin treatments enhance avian lung NK cell cytotoxicity. Int Immunopharmacol. 2003;3(2):241-252. https://pubmed.ncbi.nlm.nih.gov/12538040/
[12] Lunin SM, et al. Thymulin prevents overproduction of pro-inflammatory cytokines. Immunol Invest. 2008;37(8):858-873. https://pubmed.ncbi.nlm.nih.gov/18991101/
[13] Novoselova EG, et al. Anti-Inflammatory Effects of IKK Inhibitor XII, Thymulin. Mediators Inflamm. 2014;2014:724838. https://pmc.ncbi.nlm.nih.gov/articles/PMC4089567/
[14] Nasseri B, et al. Thymulin treatment attenuates inflammatory pain. Int Immunopharmacol. 2019;70:89-97. https://pubmed.ncbi.nlm.nih.gov/30851702/
[15] Safieh-Garabedian B, et al. Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide. Br J Pharmacol. 2002;136(3):421-428. https://pmc.ncbi.nlm.nih.gov/articles/PMC1573422/
[17] Haddad JJ, Hanbali LH. Anti-Inflammatory Activity of Thymulin Peptide is NF-kappaB-Dependent. Am J Med Biol Res. 2013;1(2):35-44. https://pubs.sciepub.com/ajmbr/1/2/2/
[21] Reggiani PC, et al. Thymulin-Based Gene Therapy and Pituitary Function in Animal Models of Aging. Neuroimmunomodulation. 2011;18(5):279-285. https://pmc.ncbi.nlm.nih.gov/articles/PMC3221262/
[22] Reggiani PC, et al. Physiology and therapeutic potential of the thymic peptide thymulin. Curr Pharm Des. 2014;20(29):4690-4696. https://pubmed.ncbi.nlm.nih.gov/24588820/
[23] Hadley AJ, et al. Thymulin stimulates corticotrophin release in the rat anterior pituitary gland. Neuroimmunomodulation. 1997;4(2):62-69. https://pubmed.ncbi.nlm.nih.gov/9483196/
[24] Reggiani PC, et al. The Thymus-Neuroendocrine Axis. Ann N Y Acad Sci. 2009;1153:98-106. https://pmc.ncbi.nlm.nih.gov/articles/PMC2688715/
[25] Dardenne M, Saade N, Safieh-Garabedian B. Role of thymulin or its analogue as a new analgesic molecule. Ann N Y Acad Sci. 2006;1088:153-163. https://pubmed.ncbi.nlm.nih.gov/17192563/
[26] Nanoparticle-based thymulin gene therapy reverses key pathology of experimental allergic asthma. Sci Adv. 2020;6(25):eaay7973. https://pmc.ncbi.nlm.nih.gov/articles/PMC7286682/

---

The peer-reviewed thymulin record, cited at the source — not a clinic, not a vendor.